Anzeige
Mehr »
Donnerstag, 02.10.2025 - Börsentäglich über 12.000 News
Starkes Upside-Potenzial: Wachstumsstory mit starken Gehalten und großem Explorationspotenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QCJL | ISIN: US8776191061 | Ticker-Symbol:
NASDAQ
02.10.25 | 18:44
4,580 US-Dollar
+43,57 % +1,390
1-Jahres-Chart
TAYSHA GENE THERAPIES INC Chart 1 Jahr
5-Tage-Chart
TAYSHA GENE THERAPIES INC 5-Tage-Chart

Aktuelle News zur TAYSHA GENE THERAPIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18:30Taysha Gene Therapies, Canaan, Ondas Holdings And Other Big Stocks Moving Higher On Thursday1
16:18Taysha soars on FDA breakthrough therapy status for lead asset3
14:59Taysha Says FDA Grants Breakthrough Therapy Designation To TSHA-102 In Rett Syndrome-
14:58FDA erteilt Sonderstatus: Aktie von Taysha Gene Therapies schießt nach oben1
14:54Taysha Gene Therapies stock soars after FDA breakthrough therapy designation1
14:18FDA grants breakthrough therapy designation to Taysha's Rett syndrome treatment4
TAYSHA GENE THERAPIES Aktie jetzt für 0€ handeln
14:10Taysha Gene Therapies, Inc. - 8-K, Current Report1
14:06Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome60Breakthrough Therapy designation granted based on FDA's review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized...
► Artikel lesen
22.09.Cantor Fitzgerald reiterates Overweight rating on Taysha Gene Therapies stock3
12.09.JMP reiterates Market Outperform rating on Taysha Gene Therapies stock1
12.09.JMP Securities bestätigt "Market Outperform" für Aktie von Taysha Gene Therapies2
05.09.Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)170DALLAS, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based...
► Artikel lesen
13.08.A Glimpse Into The Expert Outlook On Taysha Gene Therapies Through 11 Analysts2
13.08.Canaccord Genuity raises Taysha Gene Therapies stock price target on pivotal study progress3
12.08.Taysha plans pivotal TSHA-102 trial enrollment in Q4 2025, extends cash runway to 20281
12.08.Taysha Gene Therapies, Inc. - 10-Q, Quarterly Report2
12.08.Taysha Gene Therapies, Inc. - 8-K, Current Report1
12.08.Taysha Gene Therapies GAAP EPS of -$0.09 misses by $0.01, revenue of $1.99M beats by $0.39M2
12.08.Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update268Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from...
► Artikel lesen
11.08.What's Next: Taysha Gene Therapies' Earnings Preview1
Weiter >>
61 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1